Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for precision medicine and life sciences research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives. Metabolon’s expertise is accelerating research and product development across the pharmaceutical, biotechnology, consumer products, nutrition industries, as well as academic and government organizations. The company was founded in 2000.
The development of better medicine begins with better disease models. Unfortunately, current in vitro models poorly mimic the pathophysiology of fibrosis, leaving a major gap in compound screening and testing efforts in anti-fibrosis drug discovery. Xylyx Bio’s native, disease-specific extracellular matrix substrates allow drug candidates to be investigated in vitro in a disease-relevant environment, enabling cell models that are significantly more predictive of human pathophysiology. Xylyx Bio products comprise both the mechanical properties and complex ratios of ECM components specific and unique to each organ type and disease state and are available in a variety of 2D and 3D product formats to support high-throughput assays.